





MSD Assay Development and Sample Analysis

Detection by Electrochemiluminescence

ABL, Inc. offers an array of MSD-based immunoassays with a proven increase in both dynamic range and sensitivity, made possible through electrochemiluminescent labeling. ABL leverages our clinical and preclinical expertise to accurately assess clients' needs and to guide in the design of assays more sensitive than traditional ELISA. MSD assays exhibit a reduced need to repeat samples that are above the ULOQ and the electrochemiluminescence detection technology reduces background signals by separating the excitation mechanism from the signal.



In our efforts to provide the right blend of innovation and value to our clients, ABL's scientists have implemented and mastered numerous assay platforms over the years. Our recent introduction of electrochemiluminescence into our assay development arsenal is an extension of that progress. This technology can be applied to all types of traditional ELISAs, such as direct, indirect, sandwich, or competitive assays at an increased sensitivity level that can detect samples with concentrations as low as 0.1 pg/mL. Let us show you how increased sensitivity and reduced sample requirements can open new possibilities in your study.

